Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience
International Forum of Allergy & Rhinology · 2025-02 · 15 (2) · 166-173
DOI: 10.1002/alr.23466 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 18.10.2024. Verfasst von Marisa Dorling und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head & Neck Surgery, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Type 2 biologics have been used increasingly for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). However, patterns of biologic switching are understudied, and established guidelines for sequential or simultaneous use do not yet exist.
Methods
This is a Canadian multicenter retrospective study of real‐world patient data. Patients were included if they had recurrent CRSwNP despite maximal medical and surgical management, and received at least one dose of a type 2 biologic. Patients who remained on their initial biologic comprised the continuous group. Patients with sequential or simultaneous use of more than one biologic comprised the switched group. We compared the characteristics of patients who continued and switched biologics.
Results
Note that 225 consecutive patients were included. Thirty‐six (16%) switched biologics at least once, and six (3%) switched twice. The most common switch was from mepolizumab to dupilumab, with poor control of CRSwNP symptoms being the leading cause for this switch. Lack of efficacy was the main reason for switching off mepolizumab and omalizumab, while adverse events were the leading cause for switching off dupilumab. Additionally, mepolizumab patients were more likely to switch biologics late in their treatment, while dupilumab patients rarely switched after 12 months of therapy ( p ‐value < 0.001).
Conclusions
Switching biologics for CRSwNP is frequent in Canadian rhinology practices, with 16% of patients switching at least once. The most common switch is from mepolizumab to dupilumab with inadequate CRSwNP control driving this switch. This study may help guide sequential or simultaneous use of biologics in CRSwNP patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Otolaryngology-Head & Neck Surgery, University of British Columbia, Vancouver, Canada.
- Division of Otolaryngology-Head & Neck Surgery, McMaster University, Hamilton, Canada.
- Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, Canada.
ORCID-Profile: Juan Carlos Hernaiz-Leonardo, Amin Javer
Zitieren
APA
Dorling, M., Sarafan, M., Voizard, B., Ammar, Y. A., Hernaiz-Leonardo, J. C., Chalmers, K., MacInnis, P., Nugent, J., Janjua, A., Javer, A., Sommer, D., Lee, J., Chan, Y., & Thamboo, A. (2025). Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. International Forum of Allergy & Rhinology, 15(2), 166-173. https://doi.org/10.1002/alr.23466
Vancouver
Dorling M, Sarafan M, Voizard B, Ammar YA, Hernaiz-Leonardo JC, Chalmers K, et al. Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. International Forum of Allergy & Rhinology. 2025;15(2):166-173. doi:10.1002/alr.23466
BibTeX
@article{Dorling2025,
author = {Dorling, Marisa and Sarafan, Masih and Voizard, Béatrice and Ammar, Yousif Al and Hernaiz-Leonardo, Juan Carlos and Chalmers, Kieran and MacInnis, Patrick and Nugent, James and Janjua, Arif and Javer, Amin and Sommer, Doron and Lee, John and Chan, Yvonne and Thamboo, Andrew},
title = {Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
volume = {15},
number = {2},
pages = {166--173},
doi = {10.1002/alr.23466}
}
EUVIMED